Home
Sponsors
Program
Sessions
Open menu
Session 1
Session 2
Session 3
Session 4
Session 6
Session 7
Session 9
Session 10
Session 12
Session 13
Conferences
Open menu
Welcome
Closing Conference
Posters
Open menu
Poster Session 1
Poster Session 2
Poster Session 3
Poster Session 4
Round Tables
Open menu
Round Table 1
Round Table 2
Round Table 3
Meeting Policies
Menu
Home
Sponsors
Program
Sessions
Open menu
Session 1
Session 2
Session 3
Session 4
Session 6
Session 7
Session 9
Session 10
Session 12
Session 13
Conferences
Open menu
Welcome
Closing Conference
Posters
Open menu
Poster Session 1
Poster Session 2
Poster Session 3
Poster Session 4
Round Tables
Open menu
Round Table 1
Round Table 2
Round Table 3
Meeting Policies
Poster Session 2
May 19 · 10:30 - 12:30
Chairs
Georgina Coló
INIBIBB-UNS-CONICET, Bahía Blanca, Buenos Aires Argentina.
Luisa A Helguero
Institute of Biomedicine (iBiMED), University of Aveiro, Portugal.
Catalina Lodillinsky
Instituto Ángel H Roffo, Buenos Aires, Argentina.
PS2-18.
Aberrant Ret expression impacts on normal mammary gland post-lactation transition enhancing cancer potential
PS2-19.
Tristetraprolin (TTP) Expression is Required for Mammary Progenitor Cell Survival
PS2-20.
Epigenetic changes induced by pesticide exposure reactivate LINE-1 retrotransposon in breast cancer and mammary epithelial cells
PS2-21.
Norcantharidine treatment inhibits in vitro parameters associated with tumor progression in triple negative breast cancer cell lines
PS2-22.
Dual galectin-8 and ALCAM silencing delays triple negative breast cancer progression
PS2-23.
Combination therapy of paclitaxel with calcitriol analogues: a new therapeutic option for Triple Negative Breast Cancer
PS2-24.
Association between higher KI67 and higher proportion of effector T CD8 lymphocytes in HER2+ Breast Cancer patients
PS2-25.
Peripheral blood NK bright cells are augmented in breast cancer patients non-reaching pathologic complete response to antibody anti HER2+-based therapy
PS2-26.
Establishment of two Breast Cancer Patient Derived Xenograft (PDX) lines and their respective treatment-resistant PDX variant
PS2-27.
RNA-seq Identifies Nuclear ErbB-2-Induced Transcriptome as a Key Driver for Triple Negative Breast Cancer Growth
PS2-28.
Working together for the family: HER oncogenes co-amplification in breast cancer
PS2-29.
Molecular cross-talk between ER and ID4 in breast cancer
PS2-30.
Methods to monitor the relevance of M phase in the synthetic lethal potency of Polo-like Kinase 1 inhibitors
PS2-31.
Epigenetic modifications associated to breast cancer in metabolic syndrome-like disease mice models
PS2-32.
Epigenetics, bioelectricity and laterality of breast cancer
PS2-33.
Investigating the role of CBFB in breast cancer
PS2-34.
Analysis of RUNX-CBFβ as a relevant regulator of RSPO3 expression in breast cancer cells
PS2-35.
RUNX2 overexpression generates endocrine resistance in human luminal breast cancer xenografts
